The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis

Cancers (Basel). 2022 Sep 1;14(17):4287. doi: 10.3390/cancers14174287.

Abstract

Papillary thyroid cancer (PTC) often co-occurs with Hashimoto's thyroiditis, an association that has long been reported in clinical studies, remaining controversial. Experimental evidence has recently shown that pre-existing thyroiditis has a beneficial effect on PTC growth and progression by a distinctive expansion of effector memory CD8 T cells. Although the link between inflammation and PTC might involve different components of the immune system, a deep characterization of them which includes T cells, B cells and tertiary lymphoid structures, Mye-loid cells, Neutrophils, NK cells and dendritic cells will be desirable. The present review article considers the role of the adaptive and innate immune response surrounding PTC in the context of Hashimoto's thyroiditis. This review will focus on the current knowledge by in vivo and in vitro studies specifically performed on animals' models; thyroid cancer cells and human samples including (i) the dual role of tumor-infiltrating lymphocytes; (ii) the emerging role of B cells and tertiary lymphoid structures; (iii) the role of myeloid cells, dendritic cells, and natural killer cells; (iv) the current knowledge of the molecular biomarkers implicated in the complex link between thyroiditis and PTC and the potential implication of cancer immunotherapy in PTC patients in the context of thyroiditis.

Keywords: autoimmune thyroiditis; immune check point inhibitors; papillary thyroid cancer; tumor infiltrated-lymphocytes; tumor-infiltrated B lymphocytes.

Publication types

  • Review

Grants and funding

This work was in part supported by NIH grant RO1 CA194042 to Patrizio Caturegli.